Analysis10k / Blog
EN한국어ES
Reverse DCF · MRK

What MRK's Stock Price Is Really Betting On

The short answer

At today's price, Merck's stock is pricing in about 12.0% annual free-cash-flow growth for the next ten years — roughly 30% faster than its actual 5-year FCF growth (9.3% a year), a pace the market expects Merck to sustain right through Keytruda's 2028 U.S. patent expiration.

The conclusion

At its current price, MRK implies ~12.0% annual FCF growth for the next 10 years, discounted at 9%.

Merck's actual FCF growth has averaged 9.3% a year over the past 5 years; revenue grew just 7.5% a year over the same span.

Verdict: a moderately aggressive ask, right as Merck's biggest product faces a 2028 patent cliff The required growth rate (12.0%) runs about 30% above Merck's actual 5-year FCF CAGR (9.3%) and well above its 5-year revenue CAGR (7.5%) — and revenue grew just 1.3% in the most recent year alone. This isn't an extreme gap on its own, but it means the market expects Merck to sustain a somewhat faster pace than its own recent history for a full decade — a decade that includes 2028, when Keytruda, responsible for nearly half of revenue, loses U.S. patent protection.

12.0% needed vs. 9.3% actual free-cash-flow growth

Market's ask (WACC 9%)
12.0%
5-yr FCF CAGR
9.3%
5-yr revenue CAGR
7.5%
Most recent 1-yr revenue growth
1.3%

Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021-FY2025 (FCF and revenue figures).

From 9.6% to 18.3%: the discount-rate range

Required growth by discount rate: 8% gives 9.6%, 9% gives 12%, 10% gives 14.3%, 12% gives 18.3%9.6%8%12%9% (base)14.3%10%18.3%12%
Discount rate (bottom) vs. the growth the price then requires.
Required 10-year FCF growth by discount rate (WACC)
WACCRequired growthNote
8%9.6%Nearly matches the 5-yr FCF pace (9.3%)
9% (base case)12.0%Typical large-cap stable-dividend assumption
10%14.3%Clearly above historical pace
12%18.3%Well above historical pace

At 8%, the required rate (9.6%) is almost identical to Merck's actual 5-year FCF pace — a reasonable ask. Raise the discount rate to just 10%, though, and the gap widens clearly beyond what recent history supports.

What would change Merck's 12.0%

  • Using the 3-year average FCF ($13.20B) instead of FY2025's figure ($12.36B) as the base lowers the required growth rate to about 10.7% at a 9% discount rate, since 2025's FCF ran 6% below that average.
  • Treating the October 2025 Verona Pharma acquisition's debt-funded impact on net debt as a one-time event and excluding it would modestly lower the required growth rate.
  • Lowering the terminal growth rate from 2.5% to 2.0% would modestly raise the required 10-year growth rate, since more of the total value would then need to come from the explicit growth period rather than the terminal value.

The math behind 12.0%

Inputs, sources, model assumptions, and the calculation
  • Share price$148.35 — stockanalysis.com, Aug 28, 2026 close
  • Market cap$366.0B
  • Total debt$49.34B — 10-K FY2025 balance sheet (current portion $2.59B + long-term $46.75B)
  • Cash and equivalents$14.57B — 10-K FY2025 balance sheet
  • Net debt$34.77B — calculated
  • Base FCF (FY2025)$12.36B — 10-K FY2025 cash flow statement: $16.47B operating cash flow minus $4.11B capex
  • Discount rate (WACC)9% base case (8%/10%/12% tested)
  • Terminal growth rate2.5% — long-run GDP-level assumption

Normalization check: 3-year average FCF (2023-2025) is $13.20B; FY2025's figure ($12.36B) is -6.4% below that average — within the ±40% threshold, so used as-is without adjustment.

Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap plus net debt, $400.77B).

Historical CAGR check: 5-yr FCF CAGR = ($12.36B ÷ $8.674B)^(1/4) − 1 = 9.3%. 5-yr revenue CAGR = ($65.011B ÷ $48.704B)^(1/4) − 1 = 7.5%. Most recent 1-year revenue growth (2024→2025) = 1.3%.

Limits of the MRK number

This number is a starting point, not an answer
  • This isn't a fair-value price target — it only shows what the current price already assumes.
  • Change the discount rate or the FCF base, and the answer moves — see the sensitivity table above.
  • Whether 12.0% growth is realistic depends heavily on how Merck manages the 2028 Keytruda patent cliff and Gardasil's international recovery — not on this math alone.
  • A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
  • Any investment decision, and its outcome, is your own responsibility.
Built from Merck's 10-K filings (FY2021–FY2025), plus a web search for the current share price (stockanalysis.com, Aug 28, 2026). This tells you where to dig deeper — it is not a buy or sell signal.

What we'd watch next

These three checks would show whether this read is holding up. They are prompts for your own follow-up, not predictions.

  • Free cash flow vs. 12.0%The price needs about 12%; five years grew 9.3%.
  • Post-2028 growthThe ask extends right through the Keytruda expiry. Ask what fills the gap.
  • Pipeline read-outsNew launches are the counterweight. Track them.

How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.

Frequently asked questions

What growth rate does MRK's stock price assume?

At today's price, Merck's stock is pricing in about 12.0% annual free-cash-flow growth for the next ten years, at a 9% discount rate.

How does that compare to Merck's actual growth?

Merck's actual 5-year FCF CAGR (2021-2025) was 9.3% a year, and its 5-year revenue CAGR was 7.5% — both below the 12.0% the current price requires. Revenue grew just 1.3% in the most recent year alone.

What share price was used for this analysis?

This analysis used $148.35, as of the Aug 28, 2026 close.